Economics of chronic hepatitis B and hepatitis C

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 53, Issue 1, Pages (July 2010)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Volume 68, Issue 5, Pages (May 2018)
Volume 61, Issue 6, Pages (December 2014)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 44, Issue 4, Pages (April 2006)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
The place of downstaging for hepatocellular carcinoma
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 65, Issue 4, Pages (October 2016)
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 70, Issue 1, Pages (January 2019)
A dive into the complexity of type I interferon antiviral functions
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Management of cirrhosis due to chronic hepatitis C
Darius Moradpour, Arash Grakoui, Michael P. Manns 
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 44, Issue 2, Pages (February 2006)
Volume 65, Issue 1, Pages (July 2016)
Volume 50, Issue 4, Pages (April 2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Immunological techniques in viral hepatitis
Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin?  Lawrence.
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences  Zobair M. Younossi, Aybike Birerdinc,
Chronic hepatitis B in children and adolescents
Volume 62, Issue 3, Pages (March 2015)
Volume 62, Issue 4, Pages (April 2015)
Liver transplantation in children
Reply to: “Flow cytometry makes all the difference”
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
The relationship between age and fat infiltration in liver and muscle
Volume 65, Issue 4, Pages (October 2016)
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Economics of chronic hepatitis B and hepatitis C Arathi Rajendra, John B. Wong  Journal of Hepatology  Volume 47, Issue 4, Pages 608-617 (October 2007) DOI: 10.1016/j.jhep.2007.07.016 Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Cost-effectiveness plot of antiviral treatment for chronic hepatitis B [52]: This graph displays lifetime costs and quality-adjusted life years associated with single and sequential antiviral treatments for chronic hepatitis B [52]. The lines define the cost-effectiveness frontier. Any points above the line are inferior and excluded by dominance or extended dominance. The slopes of the lines equal the incremental cost-effectiveness ratio between any two strategies. Abbreviations: S, supportive care; I, Interferon; L, lamivudine; PI, peginterferon; A, adefovir. Journal of Hepatology 2007 47, 608-617DOI: (10.1016/j.jhep.2007.07.016) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions